Development

Jennifer Markarian is manufacturing reporter for Pharmaceutical Technology.

Articles

3D printing is being explored as a manufacturing method for on-demand, personalized medicine.

Considering 3D Printing for Solid Dosage Forms

The drug particle engineering and nanotechnology company offers a nanotechnology platform that can revive failed drugs in the pharma pipeline.

Nanoform Invests in Nanoparticle Technology for Drug Development

Adeline Siew is editor for Pharmaceutical Technology Europe. She is also science editor for Pharmaceutical Technology.

Senomyx uses an approach, known as taste-blocking, to address the challenges of bitter APIs. Kenneth J. Simone, vice-president of Pharmaceutical Business Development, Senomyx, speaks with Pharmaceutical Technology about this technology. 

Taste-Blocking—An Alternative to Tastemasking

The level of tastemasking required will depend on the API properties and the dosage form design.

Coating for Tastemasking

Jeff Williamson is director of Product Development at Lonza.

API-in-capsule approaches enable pharmaceutical companies to quickly assess new drug candidates with reduced API consumption and to increase speed to clinic.

Application of API-in-Capsule Best Practices to Accelerate Drug Product Development

The acquisition of Juniper expands and strengthens Catalent’s offerings in formulation development, bioavailability solutions, and clinical-scale oral dose manufacturing.

Catalent Acquires Juniper Pharmaceuticals

Pharmaceutical companies are developing new strategies to address the ever-increasing development costs for new drug therapies and maximize the value of their existing drug portfolio.

Innovating Lifecycle Management with Data-Driven and Enabling Technologies

Sai V. Nudurupati is assistant director at AbbVie Inc. (North Chicago, IL)

Michael J. Kukulka is senior manager, Global Labeling, Regulatory Affairs, PRA Health Sciences (Deerfield, IL)

Takako Ono is principal scientist, Analytical Development, Pharmaceutical Sciences, Takeda Pharmaceutical Co. Ltd. (Osaka, Japan)

Haiyan Grady is associate scientific director CMCC, Takeda Development Center Americas, 300 Massachusetts Ave (4274), Cambridge, MA 02139, Tel: 1-224-554-2067, haiyan.grady@takeda.com

This article describes the approaches used during the development of a dexlansoprazole delayed-release orally disintegrating tablet (ODT) to evaluate tablet size and texture as they relate to disintegration rate and patient experience; in addition, the resistance to alcohol was also characterized. 

Evaluation of Physical Characteristics of Dexlansoprazole Orally Disintegrating Tablets

Mark Gordon is product manager at Trelleborg Sealing Solutions Healthcare and Medical

Andrew Gaillard is global director at Trelleborg Sealing Solutions Healthcare and Medical. 

API can be mixed with silicone and other polymers to create drug-delivery combination products. 

Designing Combination Products

The extension provides four additional process development laboratories at its Nottingham site to improve output and efficiency in drug development and clinical trial manufacturing operations.

Formulation and Drug Delivery, Solid Dosage